RxDoctor Payments Data

Mary Jacqueline Galang, MD

Internal Medicine · Manteca, CANPI 1972586097

Payments from drug & device makers

$2,405in general payments, 2019–2025

Across 124 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$667
  • GSK$389
  • Boehringer Ingelheim$364
  • Novo Nordisk$329
  • Lilly USA, LLC$176
  • Sanofi-aventis U.S. LLC$160
  • plus $319 from 12 others

What the payments were for

  • Food & beverage$2,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,405 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$81,564
Medicare patients
213
Services billed
962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin175$242,711
OzempicSemaglutide123$139,101
JanuviaSitagliptin Phosphate94$126,461
EliquisApixaban70$85,916
FarxigaDapagliflozin Propanediol61$80,925
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$52,871
Humalog Kwikpen U-200Insulin Lispro33$35,316
XareltoRivaroxaban24$33,277
RybelsusSemaglutide13$33,034
MyrbetriqMirabegron16$19,456
TradjentaLinagliptin13$18,730
NamzaricMemantine Hcl/Donepezil Hcl13$18,237
Soliqua 100-33Insulin Glargine/Lixisenatide19$16,652
Humalog Kwikpen U-100Insulin Lispro56$12,091
Atorvastatin Calcium711$11,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$364$261,441188 claims
Novo NordiskOzempic, Rybelsus$329$172,135136 claims
MerckJanuvia$40$126,46194 claims
PfizerEliquis$39$85,91670 claims
AstraZenecaFarxiga, Symbicort$667$84,52673 claims
GSKTrelegy Ellipta, Arnuity Ellipta$389$54,99081 claims
AbbVieNamzaric$51$18,23713 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$160$16,65219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Manteca

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →